The calpain family, and their endogenous inhibitor calpastatin, have been implicated in cancer progression and recent
in vitro data has indicated a role in trastuzumab resistance. The aims of the current study were to examine expression levels of calpastatin, calpain-1 and calpain-2 in breast tumours from patients treated with trastuzumab following adjuvant chemotherapy, to determine their potential as biomarkers to predict therapeutic response.
»
12/07/10